ERBB2 and breast carcinoma: For example, miR-4728-3p was reported to target ESR1 (Estrogen Receptor 1) via a non-canonical seed interaction [7]; another report further demonstrated that co-amplification of miR-4278 could protect HER2-positive breast cancers from lapatinib treatment through repressing ESR1 [12].